-
Je něco špatně v tomto záznamu ?
Clinical relevance of KRAS in human cancers
S. Jancík, J. Drábek, D. Radzioch, M. Hajdúch,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NS9959
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Free Medical Journals
od 2001
PubMed Central
od 2001 do 2012
Europe PubMed Central
od 2001 do 2012
ProQuest Central
od 2007-01-01 do 2012
Open Access Digital Library
od 2001-01-01 do 2012-11-27
Open Access Digital Library
od 2001-01-01 do 2012-12-31
Open Access Digital Library
od 2001-01-01
CINAHL Plus with Full Text (EBSCOhost)
od 2006-01-01 do 2012-01-31
Medline Complete (EBSCOhost)
od 2006-01-01 do 2012-01-31
Health & Medicine (ProQuest)
od 2007-01-01 do 2012
ROAD: Directory of Open Access Scholarly Resources
od 2000 do 2012
PubMed
20617134
DOI
10.1155/2010/150960
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- nádory genetika metabolismus terapie MeSH
- protoonkogenní proteiny MeSH
- ras proteiny MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Activating mutations in the KRAS gene impair the ability of the KRAS protein to switch between active and inactive states, leading to cell transformation and increased resistance to chemotherapy and biological therapies targeting epidermal growth factor receptors. This review highlights some of the features of the KRAS gene and the KRAS protein and summarizes current knowledge of the mechanism of KRAS gene regulation. It also underlines the importance of activating mutations in the KRAS gene in relation to carcinogenesis and their importance as diagnostic biomarkers, providing clues regarding human cancer patients' prognosis and indicating potential therapeutic approaches.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026262
- 003
- CZ-PrNML
- 005
- 20140319145147.0
- 007
- ta
- 008
- 120817e20100607xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1155/2010/150960 $2 doi
- 035 __
- $a (PubMed)20617134
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jancík, Sylwia $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 775 20 Olomouc, Czech Republic.
- 245 10
- $a Clinical relevance of KRAS in human cancers / $c S. Jancík, J. Drábek, D. Radzioch, M. Hajdúch,
- 520 9_
- $a The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Activating mutations in the KRAS gene impair the ability of the KRAS protein to switch between active and inactive states, leading to cell transformation and increased resistance to chemotherapy and biological therapies targeting epidermal growth factor receptors. This review highlights some of the features of the KRAS gene and the KRAS protein and summarizes current knowledge of the mechanism of KRAS gene regulation. It also underlines the importance of activating mutations in the KRAS gene in relation to carcinogenesis and their importance as diagnostic biomarkers, providing clues regarding human cancer patients' prognosis and indicating potential therapeutic approaches.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x genetika $x metabolismus $x terapie $7 D009369
- 650 _2
- $a protoonkogenní proteiny $7 D011518
- 650 _2
- $a ras proteiny $7 D018631
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Drábek, Jirí
- 700 1_
- $a Radzioch, Danuta
- 700 1_
- $a Hajdúch, Marián
- 773 0_
- $w MED00008233 $t Journal of biomedicine & biotechnology $x 1110-7251 $g Roč. 2010(20100607), s. 150960
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20617134 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20140319145213 $b ABA008
- 999 __
- $a ok $b bmc $g 948304 $s 783608
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 2010 $d 150960 $e 20100607 $i 1110-7251 $m Journal of biomedicine and biotechnology $n J Biomed Biotechnol $x MED00008233
- GRA __
- $a NS9959 $p MZ0
- LZP __
- $a Pubmed-20120817/10/04